PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Elotuzumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 29 Jul 2016 Status changed from active, no longer recruiting to completed.
- 19 May 2015 Planned End Date changed from 1 Apr 2015 to 1 Feb 2016, according to ClinicalTrials.gov record.
- 07 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrial.gov.